Cancer immunotherapy, as a paradigm shift in cancer treatment, has recently received
tremendous attention. The active cancer vaccination, immune checkpoint blockage (ICB) …

The past decade has witnessed the explosive development of cancer immunotherapies.
Nevertheless, low immunogenicity, limited specificity, poor delivery efficiency, and off‐target …

The past decade has witnessed the accelerating development of immunotherapies for
cancer treatment. Immune checkpoint blockade therapies and chimeric antigen receptor …

Highlights•Biomaterials can potentially improve the safety and efficacy of cancer
immunotherapy.•Biomaterials scaffolds can program immune cell function in peripheral …

Immunotherapy is a promising treatment modality for cancer as it can promote specific and
durable anti-cancer responses. However, limitations to current approaches remain …

The discovery of immune checkpoint blockade has revolutionized the field of immuno‐
oncology and established the foundation for developing various new therapies that can …

Immunotherapy has made great strides in improving clinical outcomes in cancer treatment.
However, few patients exhibit adequate response rates for key outcome measures and …

Macroscale biomaterials, such as preformed implantable scaffolds and injectable soft
materials, possess powerful synergies with anti-cancer immunotherapies. Immunotherapies …

T cells are often referred to as the 'guided missiles' of our immune system because of their
capacity to traffic to and accumulate at sites of infection or disease, destroy infected or …

Cancer immunotherapies, such as immune checkpoint blockade and chimeric antigen
receptor (CAR) T cell therapy, have transformed clinical oncology. However, limited patient …